Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

Authors :: E. Fontana
A. Williams
G. Falchook
N. Lakhani
T.R.J. Evans
V. Gondi
F. Iwamoto
M. McKean
S. Symeonides
N. Butowski
A. McLaren
J. Henry
R. Buerki
J. Rotolo
G. Capiaux
R. Michel
S. Kaesshaefer
E. Wiegert
A. Bexon
Source :: European Journal of Cancer. 174:S82-S83
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools